000141144 001__ 141144
000141144 005__ 20240229105120.0
000141144 0247_ $$2doi$$a10.1158/1541-7786.MCR-17-0507
000141144 0247_ $$2pmid$$apmid:30006355
000141144 0247_ $$2ISSN$$a1044-9523
000141144 0247_ $$2ISSN$$a2377-0732
000141144 037__ $$aDKFZ-2018-01675
000141144 041__ $$aeng
000141144 082__ $$a610
000141144 1001_ $$aWang, Anthony C$$b0
000141144 245__ $$aDesmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations.
000141144 260__ $$aPhiladelphia, Pa.$$bAACR$$c2018
000141144 3367_ $$2DRIVER$$aarticle
000141144 3367_ $$2DataCite$$aOutput Types/Journal article
000141144 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555506938_13471
000141144 3367_ $$2BibTeX$$aARTICLE
000141144 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141144 3367_ $$00$$2EndNote$$aJournal Article
000141144 520__ $$aDesmoplastic infantile ganglioglioma (DIG) and desmoplastic infantile astrocytoma (DIA) are extremely rare tumors that typically arise in infancy; however, these entities have not been well characterized in terms of genetic alterations or clinical outcomes. Here, through a multi-institutional collaboration, the largest cohort of DIG/DIA to date is examined using advanced laboratory and data processing techniques. Targeted DNA exome sequencing and DNA methylation profiling were performed on tumor specimens obtained from different patients (n = 8) diagnosed histologically as DIG/DIGA. Two of these cases clustered with other tumor entities, and were excluded from analysis. The remaining 16 cases were confirmed to be DIG/DIA by histology and by DNA methylation profiling. Somatic BRAF gene mutations were discovered in 7 instances (43.8%); 4 were BRAFV600E mutations, and 3 were BRAFV600D mutations. Three instances of malignant transformation were found, and sequencing of the recurrence demonstrated a new TP53 mutation in one case, new ATRX deletion in one case, and in the third case, the original tumor harbored an EML4-ALK fusion, also present at recurrence. DIG/DIA are distinct pathologic entities that frequently harbor BRAFV600 mutations. Complete surgical resection is the ideal treatment, and overall prognosis is excellent. While, the small sample size and incomplete surgical records limit a definitive conclusion about the risk of tumor recurrence, the risk appears quite low. In rare cases with wild-type BRAF, malignant progression can be observed, frequently with the acquisition of other genetic alterations.Implications: DIG/DIA are a distinct molecular entity, with a subset frequently harboring either BRAFV600E or BRAFV600D mutations. Mol Cancer Res; 16(10); 1491-8. ©2018 AACR.
000141144 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000141144 588__ $$aDataset connected to CrossRef, PubMed,
000141144 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b1$$udkfz
000141144 7001_ $$aAbecassis, Isaac Joshua$$b2
000141144 7001_ $$00000-0002-3471-1949$$aCole, Bonnie L$$b3
000141144 7001_ $$00000-0003-0225-6184$$aLeary, Sarah E S$$b4
000141144 7001_ $$00000-0001-9036-7604$$aLockwood, Christina M$$b5
000141144 7001_ $$0P:(DE-He78)082dd3179733e3e716a58eb90f418a78$$aChavez, Lukas$$b6$$udkfz
000141144 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b7$$udkfz
000141144 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b8$$udkfz
000141144 7001_ $$aFallah, Aria$$b9
000141144 7001_ $$aWang, Shelly$$b10
000141144 7001_ $$aEne, Chibawanye$$b11
000141144 7001_ $$aOlson, James M$$b12
000141144 7001_ $$aGeyer, J Russell$$b13
000141144 7001_ $$aHolland, Eric C$$b14
000141144 7001_ $$aLee, Amy$$b15
000141144 7001_ $$aEllenbogen, Richard G$$b16
000141144 7001_ $$aOjemann, Jeffrey G$$b17
000141144 773__ $$0PERI:(DE-600)2097884-4$$a10.1158/1541-7786.MCR-17-0507$$gVol. 16, no. 10, p. 1491 - 1498$$n10$$p1491 - 1498$$tMolecular cancer research$$v16$$x1541-7786$$y2018
000141144 909CO $$ooai:inrepo02.dkfz.de:141144$$pVDB
000141144 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141144 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)082dd3179733e3e716a58eb90f418a78$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000141144 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141144 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141144 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000141144 9141_ $$y2018
000141144 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141144 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141144 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL CANCER RES : 2017
000141144 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141144 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141144 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141144 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141144 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141144 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141144 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141144 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141144 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000141144 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000141144 980__ $$ajournal
000141144 980__ $$aVDB
000141144 980__ $$aI:(DE-He78)B062-20160331
000141144 980__ $$aI:(DE-He78)G380-20160331
000141144 980__ $$aUNRESTRICTED